Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Multiple Cancer Types

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin, and cisplatin to determine the safety and maximum tolerated dose.
Lymphoma, Ovarian, Phase I
I
Berlin, Jordan
NCT02278250
VICCPHI14126

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: